$MLTX 8-K SEC Filings

Filed On	Filing
30 Sep 2026	8-K: Other Events On September 30, 2026, MoonLake Immunotherapeutics (the “Company”) submitted a Biologics License Application (“BLA”) to the U.S. Food and Drug Administration (“FDA”), seeking approval of its tri-specific nanobody sonelokimab for the trea...
10 Aug 2026	8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
15 Jul 2026	8-K: Other Events
25 Jun 2026	8-K: Entry into a Material Definitive Agreement
22 Jun 2026	8-K: Regulation FD Disclosure; Other Events
09 Jun 2026	8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders
01 Jun 2026	8-K: Entry into a Material Definitive Agreement
11 May 2026	8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
23 Feb 2026	8-K: Entry into a Material Definitive Agreement; Results of Operations and Financial Condition +4 more
08 Jan 2026	8-K: Other Events
05 Nov 2025	8-K: Entry into a Material Definitive Agreement
05 Nov 2025	8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
29 Sep 2025	8-K: Other Events
05 Aug 2025	8-K: Results of Operations and Financial Condition
06 Jun 2025	8-K: Submission of Matters to a Vote of Security Holders
12 May 2025	8-K: Results of Operations and Financial Condition
29 Apr 2025	8-K: Regulation FD Disclosure
03 Apr 2025	8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation +1 more
26 Feb 2025	8-K: Results of Operations and Financial Condition
18 Dec 2024	8-K: Departure/Election of Directors or Officers; Compensation

Comments